GlassScriptPhysician profile
Holly B Smith
NPI 1053687970
$5,577.70
in general payments reported to CMS, 2019-2025
33 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $97.17 · 2021: $515 · 2022: $613 · 2023: $897 · 2024: $657 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,771 · Education: $63.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,771.30 |
| Education | $63.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,440.62 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,185.01 | 2019-2025 | Enbrel, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $673.75 | 2019-2025 | |
| Janssen Biotech, INC. | $373.22 | 2019-2025 | Tremfya |
| Pfizer INC. | $253.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $227.42 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $176.73 | 2025 | Saphnelo |
| Ucb, INC. | $141.43 | 2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $127.19 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Horizon Therapeutics Plc | $105.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.69 | 2019-2024 | Cyltezo |
| Genentech USA, INC. | $83.91 | 2024-2025 | Actemra, Gazyva |
| Kls-Martin L.P. | $77.80 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $65.45 | 2019-2025 | Orencia |
| Shionogi INC | $53.85 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $53.50 | 2022-2024 | Zepbound, Jardiance |
| Radius Health, INC. | $52.64 | 2025 | Tymlos |
| Sandoz INC. | $51.70 | 2023-2024 | Hyrimoz |
| Tersera Therapeutics LLC | $33.04 | 2024 | Quzyttir |
| Mallinckrodt Enterprises LLC | $31.79 | 2019 | |
| Invivyd INC | $29.54 | 2025 | Pemgarda |
| Celgene Corporation | $28.50 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $24.89 | 2024 | Arcalyst |
| Tandem Diabetes Care, INC. | $24.25 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $23.30 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.73 | 2021 | |
| Novo Nordisk INC | $20.40 | 2021 | |
| Abbott Laboratories | $20.05 | 2023 | Freestyle Libre 3 |
| Amryt Pharma Holdings LTD | $19.41 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.31 | 2023 | Strensiq |
| Antares Pharma, INC. | $16.47 | 2021 | |
| Grt US Holding, INC. | $15.20 | 2022 | |
| Vyera Pharmaceuticals, LLC | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.